Controversy Question I
(2nd voting round, after speakers's presentations)

- **Should <u>neo-adjuvant breast cancer therapy response data</u> be used to accelerate drug approval?**

1. Yes
2. No
3. Don't know

Ev. Controversy Question II a

- **Should <u>only pathological complete response</u> data be considered as the “valid endpoint"?**

1. Yes
2. No
3. Don’t know

Ev. Controversy Question II b

- **Should FDA and EMA <u>consider alternatives</u> to the requirement for a randomized controlled trial, showing significantly improved survival, as the criterion for approving new drugs for breast cancer"?**

1. Yes
2. No
3. Don’t know

13th St.Gallen International Breast Cancer Conference

with Breast Cancer Treatment Consensus Update

13 -16 March, 2013, St.Gallen/Switzerland

Thank you for attending and voting !

FINIS

www.oncoconferences.ch

st.gallen oncology conferences